State Street Holds 5.2% Of Nektar — It Isn't Seeking To Change Control

The September 30 holding puts State Street alongside shareholders backing Nektar's late-stage eczema drug development.

Share
State Street Holds 5.2% Of Nektar — It Isn't Seeking To Change Control

State Street reported a 5.2% stake in Nektar Therapeutics, which develops experimental treatments for autoimmune diseases and cancer, in a passive ownership disclosure filed Tuesday. The position totaled 1,772,302 common shares as of September 30, 2026, and State Street certified that its ownership was not intended to change or influence control.

Ownership And Voting Differ

State Street's reported ownership percentage applies to Nektar's common-stock class under the disclosure's beneficial-ownership rules. September 30 is the date of the holding, rather than Tuesday's filing date.

State Street had shared voting power over 1,699,729 shares and no sole voting power. It also reported shared power to dispose of 1,772,302 shares, with no sole power to do so.

The certification places the holding within State Street's ordinary business activity. State Street said the securities were neither bought nor held to influence Nektar's control, including through participation in a transaction with that purpose.

The Eczema Bet Behind Nektar

Nektar's development effort centers on rezpegaldesleukin, a self-administered injection being studied for eczema and alopecia areata. That effort includes patients who do not respond to Dupixent or JAK inhibitors. Its global ZENITH AD eczema program reached late-stage trials.

The company has a cash runway extending into the third quarter of 2028 to pursue its development plans. Its pipeline also includes NKTR-255, designed to stimulate the immune system against cancer.

Nektar licenses drug technologies to biotechnology and pharmaceutical companies under agreements that can bring milestone payments and royalties. More than ten products using its PEGylation technology—attaching a polymer to a drug—have received approval in the U.S. or Europe through collaborations and licensing partnerships.

Those development efforts sit beside a valuation comparison: Sasha Jovanovic, writing in Yahoo Finance commentary, put Nektar's shares at 22.6 times sales, more than double the biotech industry average.

Nektar's market capitalization was $1.3 billion in Tuesday trading as of 9:19 a.m. ET.

Sources